Business Context and Reporting Period
Company: Elutia Inc. (ELUT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Elutia develops proprietary drug-eluting biomatrix products for surgical reconstruction. Following the October 2025 divestiture of its Cardiac Implantable Electronic Device (CIED) business to Boston Scientific and Cardiac Pacemakers, the Company now operates two segments: Women's Health (SimpliDerm) and Cardiovascular (ProxiCor, VasCure, Tyke). The Company is advancing its next-generation drug-eluting biomatrix platform, specifically NXT-41 and NXT-41x, targeting breast reconstruction and soft tissue repair markets.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Net Sales | $12,293 | $14,467 |
| Gross Profit | $6,596 | $6,715 |
| Gross Margin | 53.7% | 46.4% |
| Loss from Continuing Operations | $(26,911) | $(30,712) |
| Income from Discontinued Operations | $69,251 | $(8,604) |
| Net Income (Loss) | $53,380 | $(53,949) |
| Cash and Cash Equivalents (Year End) | $36,350 | $13,239 |
| Long-Term Debt | $0 | $22,603 |
Note: 2025 Net Income is driven primarily by a $76.1 million gain on the sale of the CIED business, reported as discontinued operations. Continuing operations remain unprofitable.
Material Changes vs. Prior Period
- Divestiture of CIED Business: On October 1, 2025, Elutia sold its CIED business (EluPro, CanGaroo) for up to $88.0 million ($80.4 million paid at closing, $8.0 million in escrow). This resulted in a $76.1 million gain, net of tax and divestiture costs, and the repayment of the $27.8 million SWK Loan Facility.
- Revenue Decline: Net sales from continuing operations decreased 15.0% to $12.3 million. Women's Health sales dropped 20.9% due to the termination of the distribution agreement with Tiger Aesthetics Medical in October 2025. Cardiovascular sales increased 8.3% following the resumption of direct sales after terminating the LeMaitre Vascular agreement.
- Margin Expansion: Gross margin improved to 53.7% from 46.4%, driven by higher end-user pricing in direct sales channels compared to distributor contracts.
- Litigation Costs: Net litigation costs decreased 25.2% to $8.5 million, reflecting settlements in FiberCel cases. However, the Company has exhausted insurance coverage for FiberCel liabilities, leaving a $6.8 million contingent liability fully on its balance sheet.
- Debt Elimination: The Company repaid its entire SWK Loan Facility ($26.9 million principal plus fees) using proceeds from the CIED sale, eliminating long-term debt.
Guidance, Outlook, and Risks
- Product Pipeline: Management expects FDA clearance for NXT-41 in the second half of 2026 and NXT-41x by mid-2027. These products combine biologic scaffolds with local antibiotic delivery to reduce surgical complications.
- Liquidity: As of December 31, 2025, the Company held $36.4 million in cash. Management believes this is sufficient to fund operations for at least one year, though future capital raises may be necessary to fund NXT-41x commercialization.
- Key Risks:
- Litigation Exposure: Significant contingent liability ($11.2 million total) related to FiberCel and Viable Bone Matrix (VBM) recalls. FiberCel insurance is exhausted; VBM insurance remains available.
- Profitability: The Company expects to continue incurring operating losses from continuing operations as it invests in R&D for NXT-41x.
- Regulatory: Success depends on obtaining FDA clearances for NXT-41 and NXT-41x. Delays or denials would materially harm the business.
- Supplier Concentration: Reliance on single-source suppliers (Berkeley for SimpliDerm; Cook/Evergen for Cardiovascular raw materials).
Investor Verification Checklist
- Insurance Coverage Status: Verify the extent of remaining insurance coverage for VBM litigation and confirm the $6.8 million FiberCel liability is fully self-insured.
- Discontinued Operations Gain: Confirm the $76.1 million gain is non-recurring and excluded from future operating projections.
- NXT-41x Timeline: Monitor FDA submission dates and clearance expectations for NXT-41 (H2 2026) and NXT-41x (mid-2027).
- Cash Burn Rate: Assess whether the $36.4 million cash balance is sufficient to cover operating losses and R&D costs until NXT-41x generates revenue or additional capital is raised.
- Supplier Agreements: Review the terms of the supply agreements with Berkeley and Cook/Evergen for potential disruption risks.